The cyclodepsipeptide jasplakinolide (1) (aka jaspamide), isolated previously from the marine sponge Jaspis splendens, is a unique cytotoxin and molecular probe that operates through stabilization of filamentous actin (F-actin). We have recently disclosed that two analogues of 1, jasplakinolides B (3) and E, were referred to the National Cancer Institute's (NCI) Biological Evaluation Committee, and the objective of this study was to reinvestigate a Fijian collection of J. splendens in an effort to find jasplakinolide congeners with similar biological properties. The current efforts have afforded six known jasplakinolide analogues (4-7, 9, 10), two structures requiring revision (8 and 14), and four new congeners of 1 (11-13, 15) including open-chain derivatives and structures with modified β-tyrosine residues. Compounds were evaluated for biological activity in the NCI's 60 cell line screen and in a microfilament disruption assay in both HCT-116 and HeLa cells. These two phenotypic screens provide evidence that each cytotoxic analogue, including jasplakinolide B (3), operates by modification of microfilaments. The new structure jasplakinolide V (13) has also been selected for study by the NCI's Biological Evaluation Committee. In addition, the results of a clonogenic dose-response study on jasplakinolide are presented.
The cyclodepsipeptiden class="Chemical">jasplakinolide (1) (aka jaspamide), isolated previously from the marine sponge Jaspis splendens, is a unique cytotoxin and molecular probe that operates through stabilization of filamentous actin (F-actin). We have recently disclosed that two analogues of 1, jasplakinolides B (3) and E, were referred to the National Cancer Institute's (NCI) Biological Evaluation Committee, and the objective of this study was to reinvestigate a Fijian collection of J. splendens in an effort to find jasplakinolide congeners with similar biological properties. The current efforts have afforded six known jasplakinolide analogues (4-7, 9, 10), two structures requiring revision (8 and 14), and four new congeners of 1 (11-13, 15) including open-chain derivatives and structures with modified β-tyrosine residues. Compounds were evaluated for biological activity in the NCI's 60 cell line screen and in a microfilament disruption assay in both HCT-116 and HeLa cells. These two phenotypic screens provide evidence that each cytotoxic analogue, including jasplakinolide B (3), operates by modification of microfilaments. The new structure jasplakinolide V (13) has also been selected for study by the NCI's Biological Evaluation Committee. In addition, the results of a clonogenic dose-response study on jasplakinolide are presented.
Authors: Stefania Terracciano; Ines Bruno; Giuseppe Bifulco; Jean E Copper; Charles D Smith; Luigi Gomez-Paloma; Raffaele Riccio Journal: J Nat Prod Date: 2004-08 Impact factor: 4.050
Authors: Stefania Terracciano; Ines Bruno; Giuseppe Bifulco; Elvira Avallone; Charles D Smith; Luigi Gomez-Paloma; Raffaele Riccio Journal: Bioorg Med Chem Date: 2005-09-01 Impact factor: 3.641
Authors: Alexander Zhdanko; Anke Schmauder; Christopher I Ma; L David Sibley; David Sept; Florenz Sasse; Martin E Maier Journal: Chemistry Date: 2011-10-20 Impact factor: 5.236
Authors: Tyler A Johnson; Johann Sohn; Wayne D Inman; Samarkand A Estee; Steven T Loveridge; Helene C Vervoort; Karen Tenney; Junke Liu; Kenny Kean-Hooi Ang; Joseline Ratnam; Walter M Bray; Nadine C Gassner; Young Y Shen; R Scott Lokey; James H McKerrow; Kyria Boundy-Mills; Arif Nukanto; Atit Kanti; Heddy Julistiono; Leonardus B S Kardono; Leonard F Bjeldanes; Phillip Crews Journal: J Nat Prod Date: 2011-11-30 Impact factor: 4.050
Authors: Vinayak Agarwal; Zachary D Miles; Jaclyn M Winter; Alessandra S Eustáquio; Abrahim A El Gamal; Bradley S Moore Journal: Chem Rev Date: 2017-01-20 Impact factor: 60.622
Authors: Sheng Lin; Erin P McCauley; Nicholas Lorig-Roach; Karen Tenney; Cassandra N Naphen; Ai-Mei Yang; Tyler A Johnson; Thalia Hernadez; Ramandeep Rattan; Frederick A Valeriote; Phillip Crews Journal: Mar Drugs Date: 2017-03-29 Impact factor: 5.118
Authors: James J La Clair; Steven T Loveridge; Karen Tenney; Mark O'Neil-Johnson; Eli Chapman; Phillip Crews Journal: PLoS One Date: 2014-07-08 Impact factor: 3.240